STIMULATION AND PRIMING OF HUMAN NEUTROPHILS BY IL-1-ALPHA AND IL-1-BETA - COMPLETE INHIBITION BY IL-1 RECEPTOR ANTAGONIST AND NO INTERACTION WITH OTHER CYTOKINES

被引:0
作者
YAGISAWA, M
YUO, A
KITAGAWA, S
YAZAKI, Y
TOGAWA, A
TAKAKU, F
机构
[1] INT MED CTR JAPAN,RES INST,SHINJUKU KU,TOKYO 162,JAPAN
[2] INT MED CTR JAPAN,DEPT HEMATOL,SHINJUKU KU,TOKYO 162,JAPAN
[3] UNIV TOKYO,FAC MED,DEPT INTERNAL MED 3,TOKYO 113,JAPAN
[4] JICHI MED SCH,INST HEMATOL,MINAMI KAWACHI,TOCHIGI 32904,JAPAN
关键词
IL-1; IL-1 RECEPTOR ANTAGONIST; NEUTROPHILS; SUPEROXIDE;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Together, interleukin-1 alpha (IL-1 alpha) and IL-1 beta primed human neutrophils for enhanced release of superoxide (O-2(-)) stimulated by chemotactic peptide, chemokine, and plant lectin, and alone, each triggered O-2(-) release in a dose-dependent manner. The maximal priming and triggering effect was obtained by high concentrations (50 to 500 ng/mL) of IL-1 alpha or IL-1 beta, though IL-1 beta was more effective than IL-1 alpha at suboptimal concentrations. Priming effect of IL-1 was very rapid and maximal within 10 minutes, whereas O-2(-) release triggered by IL-1 was gradual and continued for 90 to 120 minutes. Combined stimulation of human neutrophils with IL-1 plus granulocyte colony-stimulating factor (G-CSF) or granulocyte-macrophage CSF (GM-CSF) resulted in additive priming effect, and combined stimulation of neutrophils with IL-1 plus G-CSF, GM-CSF, or tumor necrosis factor (TNF) resulted in additive triggering effect, even when the maximal concentration of each cytokine was used. These priming and triggering effects of IL-1 alpha and IL-1 beta on the respiratory burst in human neutrophils were completely inhibited by IL-1 receptor antagonist (IL-1ra). Furthermore, only the net effect of IL-1 was inhibited by IL-1ra, even when human neutrophil was stimulated with IL-1 plus other cytokines to release O-2(-). Present results indicate that IL-1 does stimulate the respiratory burst activity in human neutrophils via receptor-mediated mechanism and suggest that the post-IL-1-receptor signaling pathways linked to the activation system of the respiratory burst are independent from those utilized by other cytokines in human neutrophils.
引用
收藏
页码:603 / 608
页数:6
相关论文
共 19 条
[1]   INTERLEUKIN-1 RECEPTOR ANTAGONIST - A NEW MEMBER OF THE INTERLEUKIN-1 FAMILY [J].
AREND, WP .
JOURNAL OF CLINICAL INVESTIGATION, 1991, 88 (05) :1445-1451
[2]  
BENSIMON C, 1989, J IMMUNOL, V143, P1168
[3]  
DINARELLO CA, 1991, BLOOD, V77, P1627
[4]   RECOMBINANT HUMAN INTERLEUKIN-1 BETA-PRIMES HUMAN POLYMORPHONUCLEAR LEUKOCYTES FOR STIMULUS-INDUCED MYELOPEROXIDASE RELEASE [J].
DULARAY, B ;
ELSON, CJ ;
CLEMENTSJEWERY, S ;
DAMAIS, C ;
LANDO, D .
JOURNAL OF LEUKOCYTE BIOLOGY, 1990, 47 (02) :158-163
[5]   EFFECTS OF TUMOR NECROSIS FACTOR-ALPHA AND INTERLEUKIN-1-ALPHA AND INTERLEUKIN-1-BETA ON HUMAN NEUTROPHIL MIGRATION, RESPIRATORY BURST AND DE-GRANULATION [J].
FERRANTE, A ;
NANDOSKAR, M ;
WALZ, A ;
GOH, DHB ;
KOWANKO, IC .
INTERNATIONAL ARCHIVES OF ALLERGY AND APPLIED IMMUNOLOGY, 1988, 86 (01) :82-91
[6]   TYROSINE PHOSPHORYLATION IN HUMAN NEUTROPHIL [J].
GOMEZCAMBRONERO, J ;
HUANG, CK ;
BONAK, VA ;
WANG, E ;
CASNELLIE, JE ;
SHIRAISHI, T ;
SHAAFI, RI .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1989, 162 (03) :1478-1485
[7]   INTERLEUKIN-1 AND TUMOR NECROSIS FACTOR INCREASE PHOSPHORYLATION OF FIBROBLAST PROTEINS [J].
KAUR, P ;
SAKLATVALA, J .
FEBS LETTERS, 1988, 241 (1-2) :6-10
[8]   A NOVEL IL-1 RECEPTOR, CLONED FROM B-CELLS BY MAMMALIAN EXPRESSION, IS EXPRESSED IN MANY CELL-TYPES [J].
MCMAHAN, CJ ;
SLACK, JL ;
MOSLEY, B ;
COSMAN, D ;
LUPTON, SD ;
BRUNTON, LL ;
GRUBIN, CE ;
WIGNALL, JM ;
JENKINS, NA ;
BRANNAN, CI ;
COPELAND, NG ;
HUEBNER, K ;
CROCE, CM ;
CANNIZZARRO, LA ;
BENJAMIN, D ;
DOWER, SK ;
SPRIGGS, MK ;
SIMS, JE .
EMBO JOURNAL, 1991, 10 (10) :2821-2832
[9]  
OKUDA K, 1992, BLOOD, V79, P2880
[10]   POTENTIATION OF NEUTROPHIL FUNCTION BY RECOMBINANT DNA-PRODUCED INTERLEUKIN-1A [J].
OZAKI, Y ;
OHASHI, T ;
KUME, S .
JOURNAL OF LEUKOCYTE BIOLOGY, 1987, 42 (06) :621-627